Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Moves into the Black as Q3 Revenues Rise 6 Percent

NEW YORK (GenomeWeb News) - Swedish life sciences technology firm Biotage posted a 6 percent increase in third-quarter revenues yesterday, as a loss in the prior-year quarter swung into a profit.
Sales for the quarter ended Sept. 30 rose to SEK 133.9 million ($18 million) from SEK 126.6 million ($17.3 million) in the third quarter of 2005.
Revenues for the firm’s discovery chemistry business increased 7 percent, to SEK 111.5 million, while biosystems revenues were relatively flat at SEK 22.4 million.
Biotage posted a net profit of SEK 8.6 million, compared to a loss of SEK 27.6 million in the year-ago quarter.
R&D spending dipped to SEK 13.8 million from SEK 17.8 million in the third quarter of 2005.
As of Sept. 30, Biotage had SEK 32.3 million in cash and liquid assets.
Pointing to steady increases in cash flow and sales, the company said it has finally integrated acquisitions it made last year, has seen steady improvement in its US market and recently has been re-investing in patents, rights and hard capital. 

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.